Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China-Reference-Cited by-同舟云学术

Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China

Published:2024-02 Issue:6 Volume:22 Page:469-477
ISSN:1478-7210
Container-title:Expert Review of Anti-infective Therapy
language:en
Short-container-title:Expert Review of Anti-infective Therapy

Author:

Li Pulin¹,Huang Ling²,Han Rui¹,Tang Min¹,Fei Guanghe¹,Zeng Daxiong³⁴,Wang Ran¹

Affiliation:

1. Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, China

2. Department of Infectious Disease, Hefei Second People’s Hospital, Hefei, China

3. Department of Pulmonary and Critical Care Medicine, Dushu Lake Hospital Affiliated to Soochow University, Medical Center of Soochow University, Suzhou, China

4. Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, China

Funder

Research Fund project of Anhui Medical University

Young Jianghuai famous medical training project, and Excellent physician Training program of Anhui Medical University

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14787210.2024.2309998

Reference49 articles.

1. Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes

2. A Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2

3. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

4. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines

5. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir